Grow your brand or monetize your platform with AdLuxe Network, where premium ad solutions meet performance.
Summary
- Eli Lilly's Orforglipron shows promising Phase III results, potentially becoming a best-in-class oral GLP-1 receptor agonist for diabetes and obesity by 2026.
- Despite macroeconomic headwinds, Lilly's strong pipeline and market leadership in incretin analogues support a "Buy" rating for long-term investors with DCA strategy.
- Lilly's oncology and neuroscience sectors are progressing, with significant investments in U.S. manufacturing to mitigate potential Pharma Tariffs impact.
- Wall Street projects significant revenue and EPS growth for LLY, with a 17% upside potential, despite market volatility and macroeconomic uncertainties.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
English (US) ·